InfraReDx debuts TVC imaging system

Burlington, MA-based InfraReDx has launched its TVC imaging system (pictured), the only FDA-approved device for the detection of lipid core plaques (LCP) of interest, according to a company release. The system is being unveiled this week at the annual Transcatheter Cardiovascular Therapeutics Meeting in San Francisco.

The company's latest offering is an intravascular imaging system that provides information for evaluating vessel structure and composition. The system's improved image resolution offers enhanced clinical detail, providing more reliable vessel interpretation and assessment. The TVC imaging system and its ability to detect LCPs helps interventional cardiologists identify those at risk of stenting complications, allowing for more tailored interventional treatment strategies.

"InfraReDx is committed to helping interventional cardiologists deliver the best possible care for their patients by providing intravascular imaging solutions that are easy to use and produce a more complete view of the vessel's structure and composition," said Donald Southard, president and CEO of InfraReDx. "The TVC imaging system provides this additional information by combining high quality IVUS imaging with InfraReDx's proprietary NIRS technology for compositional assessment. We are pleased to announce that this next generation platform technology is now available to customers in the U.S. as well as in Europe."

Earlier this year, InfraReDx raised $24.1 million from the sale of equity to existing shareholders. The company said it would use the proceeds to expand manufacturing operations and commercial infrastructure to support demand for the LipiScan IVUS coronary imaging system, which was launched in September 2010. The funds also will be used to support ongoing and new clinical trials investigating expanded applications of the system, the company said at the time. 

- get the InfraReDx release

Suggested Articles

Seven developers will provide digital health solutions aimed at the COVID-19 pandemic, including smartphone apps, wearables and big data programs.

Illumina will drop $8 billion to reacquire its former spinout, which after nearly five years is nearing completion of its cancer-seeking blood test.

The CE Mark for the system’s fourth iteration follows a July 2019 approval from the FDA.